Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

USRM RSS Feed
Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Taurus69, Flippin Stocks, poor500
Search This Board: 
Last Post: 3/29/2020 5:10:54 AM - Followers: 762 - Board type: Free - Posts Today: 3


http://us-stemcell.com/en/home-2/
http://stemcellcoe.com
http://usstemcellclinic.com/en/home/
https://www.usstemcelltraining.com
http://www.vetbiologics.com



A COMMITMENT TO EXCELLENCE

US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director
     
     

 

 

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.


Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


     
     
     




    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here: https://www.ncbi.nlm.nih.gov/pubmed/21982657).  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm


     
    
USRM - Daily Candlesticks








SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>https://www.prnewswire.com/news-releases/usrm-stem-cell-treatment-shows-promise-in-enhancing-erectile-function-300578817.html

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida    https://www.instagram.com/p/BeCDtYqFX8I/?hl=en&taken-by=bengreenfieldfitness

Expecting Ben Greenfield's article to be found here once written any day now... https://www.menshealth.com/author/ben-greenfield



Press Releases:
http://www.otcmarkets.com/stock/USRM/news

USRM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Statement of Changes in Beneficial Ownership (4) 12/20/2019 04:18:49 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/20/2019 04:15:51 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/20/2019 04:12:30 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/20/2019 04:06:01 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/20/2019 04:02:41 PM
PostSubject
#102631  Sticky Note U.S. Stem Cell, Inc., formerly Bioheart, Inc., is poor500 02/01/20 07:15:26 AM
#102591  Sticky Note I bought back in last week, still had RMS555 01/31/20 05:22:15 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#103336   $usrm $.0055 Taurus69 03/29/20 05:10:54 AM
#103335   Can we maybe use this as forward looking emit 03/29/20 01:22:41 AM
#103334   On the other side of the locked door. emit 03/29/20 12:59:53 AM
#103333   Anyone see their Facebook story??? Picture of Jbird17 03/28/20 07:42:01 PM
#103332   What's set to happen? emit 03/28/20 04:37:57 PM
#103331   FWIW' emit 03/28/20 04:30:54 PM
#103328   LOL, Everyone should realize that appeal court date Dragon Lady 03/27/20 08:17:06 PM
#103327   thanks for the update! RMS555 03/27/20 07:14:32 PM
#103326   Everyone should realize that appeal court date for Bigdog123 03/27/20 05:48:01 PM
#103325   Added to my position today! Looking to add Jbird17 03/27/20 03:14:49 PM
#103324   8 weeks ago was when the run started RMS555 03/27/20 12:35:24 PM
#103323   Looks like someone put the brakes on a Atom Smasher 03/27/20 12:28:14 PM
#103322   it would be real nice to see that RMS555 03/27/20 12:23:07 PM
#103321   Will the case be delayed now? BluSkies 03/27/20 10:56:25 AM
#103320   We should be posting this video interview everywhere Hippycowboy 03/26/20 11:27:14 AM
#103319   Sounds good to me! 4toSchool 03/26/20 11:21:58 AM
#103318   She also mentioned stem cells can help heal Hippycowboy 03/26/20 11:18:54 AM
#103317   thanks for sharing, hopefully we hear/see something soon! RMS555 03/25/20 11:01:49 AM
#103316   She said we're still doing bone-marrow SCs. emit 03/25/20 02:51:33 AM
#103315   USRM Today' StemCells and Corona emit 03/24/20 11:59:58 PM
#103314   $usrm $.00461 Taurus69 03/23/20 09:37:57 PM
#103313   With California on "lock down" I wouldn't be TheWhigs 03/23/20 01:22:12 PM
#103312   It’s better to have them late then never StockBull 03/21/20 04:35:21 PM
#103311   $usrm $.00465 Taurus69 03/21/20 05:49:02 AM
#103310   Yea I can see that sorc92 03/20/20 03:07:17 PM
#103309   Don't be surprised if it's rescheduled for a FIREST1 03/20/20 03:05:25 PM
#103308   That was nice for USRM CEO to provide TheWhigs 03/19/20 12:29:34 AM
#103307   No after we kick the gov butt in sorc92 03/19/20 12:14:36 AM
#103305   CEO: 10-K filing LATE, NOT GOOD. Oh oh ????? Dragon Lady 03/18/20 02:38:53 PM
#103304   Updated today. Wolfe64 03/18/20 01:37:54 PM
#103303   I picked up lil more today' emit 03/16/20 04:06:02 PM
#103302   Sure looks like it is following the major markets JoeJoeyoyo 03/16/20 02:09:31 PM
#103301   Will be buying back in next week abazaba375 03/14/20 01:10:58 PM
#103300   oh. i see that USRM followed the bounce JoeJoeyoyo 03/14/20 07:21:01 AM
#103299   Maybe peeps haven't noticed but, the entire market's trading.jeff 03/13/20 10:31:14 AM
#103298   Well what about the prior 2 years? It JoeJoeyoyo 03/13/20 10:12:44 AM
#103297   The stock market is getting hammered because of GetRichorGetHighTryn 03/12/20 09:00:37 PM
#103296   Slap it good while they ARE looking kaos2k 03/12/20 03:57:34 PM
#103295   I feel sorta insulated on this one with kaos2k 03/12/20 11:23:16 AM
#103294   I just don't see how you can claim Wolfe64 03/11/20 02:15:08 PM
#103293   @RMS555 - thanks for taking the time to explain. TheWhigs 03/11/20 09:55:17 AM
#103292   Someone "big" from the Company that has shares, RMS555 03/10/20 09:08:53 PM
#103291   Looks like we will have to agree to disagree GetRichorGetHighTryn 03/10/20 09:00:36 PM
#103290   Thanks for the info. :-) TheWhigs 03/10/20 08:56:50 PM
#103289   Share Structure updated with yesterdays date...... Same amount RMS555 03/10/20 10:36:26 AM
#103288   Might just be a flipper stock. Buy low Wolfe64 03/10/20 09:04:29 AM
#103287   Literally has nothing to do with Corona. It's Wolfe64 03/10/20 09:03:54 AM
#103286   Once this pesky Coronavirus blows over we'll be GetRichorGetHighTryn 03/09/20 07:20:36 PM
#103285   They should just go dirty and pump news Wolfe64 03/09/20 08:27:50 AM
#103284   This is not a bad idea, probably the trading.jeff 03/08/20 02:11:11 PM
PostSubject